Protara Therapeutics
TARA
16 hedge funds and large institutions have $2.9M invested in Protara Therapeutics in 2019 Q4 according to their latest regulatory filings, with 5 funds opening new positions, 6 increasing their positions, 3 reducing their positions, and 6 closing their positions.
119% more capital invested
Capital invested by funds: $1.33M → $2.9M (+$1.57M)
100% more repeat investments, than reductions
Existing positions increased: 6 | Existing positions reduced: 3
0.11% more ownership
Funds ownership: 0.65% → 0.76% (+0.11%)
6% less funds holding
Funds holding: 17 → 16 (-1)
17% less first-time investments, than exits
New positions opened: 5 | Existing positions closed: 6
100% less funds holding in top 10
Funds holding in top 10: 1 → 0 (-1)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
DM
Deerfield Management
New York
|
+$231K |
| 2 |
PA
Perceptive Advisors
New York
|
+$98K |
| 3 |
OM
Opaleye Management
Boston,
Massachusetts
|
+$38.5K |
| 4 |
A
Abingworth
London,
United Kingdom
|
+$36.3K |
| 5 |
Renaissance Technologies
New York
|
+$22K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
DVC
Deer VII & Co
Larchmont,
New York
|
-$82K |
| 2 |
VF
Virtu Financial
New York
|
-$23K |
| 3 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$17.1K |
| 4 |
BFM
Boothbay Fund Management
New York
|
-$15K |
| 5 |
UBS Group
Zurich,
Switzerland
|
-$6.86K |
TARA Hedge Fund Activity: Q4 2019 in Review
16 of the 5,092 institutional investors tracked by Wall St. Rank reported a position in Protara Therapeutics (TARA) for Q4 2019, worth a combined $2.9M — up 119% from $1.33M a quarter earlier.
Sellers outnumbered buyers: 6 funds closed out of TARA and 5 opened new positions — a net loss of 1 holder — while 3 trimmed existing stakes and 6 added.
The largest buyer was Deerfield Management, adding an estimated $231K. The largest seller was Deer VII & Co, exiting entirely with an estimated $82K sold.
- 16 institutional investors held Protara Therapeutics (TARA) as of Q4 2019, down from 17 in Q3 2019.
- Funds reported $2.9M of Protara Therapeutics stock for Q4 2019, up 119% quarter-over-quarter.
- 5 funds opened new Protara Therapeutics positions in Q4 2019 and 6 closed out, a net change of -1 holder.
- The largest Protara Therapeutics buyer in Q4 2019 was Deerfield Management, an estimated $231K added.
- The largest Protara Therapeutics seller in Q4 2019 was Deer VII & Co, an estimated $82K sold.
Based on aggregated 13F filings for Q4 2019.